Prevalence of peripheral neuropathy among type 2 diabetes mellitus patients in a rural health centre in South India

Jasmine, Aliya; Shriraam, Vanishree; Durai, Vanitha; Rani, M. Anitha; Samya, V; Akila, G V; Gayathri, T; Mahadevan, Shriraam

doi:10.1007/s13410-020-00885-6

Cited by 13 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 21 ] Jasmine et al . [ 22 ] reported a similar prevalence of 44.9% in a rural area in Chennai, though they had used a different study instrument.…”

Section: Discussionmentioning

confidence: 99%

Diabetic peripheral neuropathy in diabetic patients attending an urban health and training centre

Kamalarathnam

Varadarajan

2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Introduction: Diabetic neuropathy is a complication affecting almost 50% of the diabetic patients. Diabetic Peripheral Neuropathy (DPN) predominantly affects the hands and lower limbs. It leads to loss of protective sensation resulting in continuous injury to insensitive feet. The early detection of DPN using an objective screening test followed by its appropriate management is important as up to 50% of the patients may be asymptomatic. Objectives: To screen Diabetic patients attending an Urban Health and Training Centre of a medical college in Tamilnadu for Diabetic Peripheral Neuropathy. To assess the association between DPN and selected variables such as socio-demographic factors, glycaemic control, duration of diabetes, physical activity, body mass index, smoking and consumption of alcohol. Methods: The study was conducted among 204 diabetic patients attending an Urban Health and Training Centre. Participants were assessed using Michigan Neuropathy Screening Instrument (MNSI), which involves using a questionnaire followed by a physical examination. Results: Of the 204 patients, 58.8% were male. The mean age was 54.8 years (SD = 8.8 years). About 79.9% were employed of which 29.4% were skilled labourers. Mean duration of diabetes was 6.2 years (SD = 5.3 years). The proportion of diabetics who screened positive for Peripheral Neuropathy was 23% and 45.6% using MNSI questionnaire and examination, respectively. An age of 60 years and above was significantly associated with DPN (OR = 2.505, P value = 0.003). A duration of more than 4 years of diabetes was also significantly associated with DPN (OR = 1.872, P value = 0.02820). Conclusion: A high proportion of diabetics with peripheral neuropathy did not express symptoms specific for diabetics. Thus, a simple tool like MNSI would be useful in primary care settings to screen for peripheral neuropathy, and hence prevent disability”.

show abstract

“…[ 21 ] Jasmine et al . [ 22 ] reported a similar prevalence of 44.9% in a rural area in Chennai, though they had used a different study instrument.…”

Section: Discussionmentioning

confidence: 99%

Diabetic peripheral neuropathy in diabetic patients attending an urban health and training centre

Kamalarathnam

Varadarajan

2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

show abstract

“…Some recent DPN studies from India have shown prevalence—31% in rural south India,[ 8 ] 34% in Rajasthan,[ 9 ] and 45% in urban south India. [ 10 ] As VPT values correlate well with severity of DPN,[ 11 ] we used mild, moderate, and severe grades of VPT and DPN was distributed in 10%, 20%, and 38%, respectively. As suggested by a recent work in China,[ 4 ] if we use VPT cut off 15, then the presence of DPN of varying degree would be 68% in study population.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and correlates of vibration perception threshold based diabetic peripheral neuropathy in Gujarati urban population: A cross sectional study

Solanki

Doshi²,

Virani³

et al. 2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

A BSTRACT Background: Diabetic peripheral neuropathy (DPN) is common microvascular complication with lack of data from many regions. Vibration perception threshold (VPT) is an objective tool to screen vibration-based neuropathy both quantitatively and qualitatively. We studied prevalence that correlates VPT in diabetic sample population. Methods: A cross-sectional study was performed in 100 under treatment urban type 2 diabetics. Using bioesthesiometer, we tested VPT from sole of lower limbs of each participant. VPT >25 was considered as DPN. VPT was further correlated to determinants using t test, chi square, and multiple linear regressions. P < 0.05 was taken as statistically significant. Results: Mean age was 57, mean duration was 9.42 years, 40% were good glycemic, 28% were symptomatic for neuropathy, half subjects had co-existing hypertension and positive family history. VPT >25 was prevalent in 38% participants and mild, moderate, severe grades of DPN were present in 10%, 20%, 38%, respectively. VPT was associated with all three measures of glycemic control both quantitatively and qualitatively imposing significant odds risk (3.45, 2.63, 3.63 for HbA1C, FPG, 2hPG, respectively). Presence of symptoms, duration, and family history were significant predictors of VPT, whereas age, gender, hypertension, hyperlipidemia, and glycemic control were not. Conclusion: In chronic type 2 diabetics from a city Gujarat, we report 38% prevalence of DPN, related to symptoms, duration, family history, and all measures of glycemic triad. Unrelated to age and gender, VPT is superior to symptoms to detect DPN and it should be used optimally to insinuate timely preventive measures.

show abstract

“…In India 8.9% of the population suffers from diabetes according to the latest report of IDF. The prevalence rate of DN in India is about 18.9-61.9% [3]. Globally, around 132 million people are affected by DN, which is about 1.9% of the world population [4].…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of oral Alpha lipoic acid in the management of Diabetic Neuropathy: A Systematic Review and Meta-analysis

Das,

Viswanatha,

Kishore

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective:To evaluate the efficacy and safety of oral alpha lipoic acid for the management of diabetic neuropathy. Methods: A detailed literature search was performed using databases like Pubmed, Embase, and Google Scholar. The search was mainly focused on randomised controlled trials (RCTs) for evaluating the safety and efficacy of alpha-lipoic acid in managing diabetic neuropathy. Based on inclusion and exclusion criteria Eight studies were selected. Data were extracted to examine the quality and characteristics of the studies. Primary outcomes were HbA1c, neuropathy impairment score (NIS), neuropathy impairment score-low limb (NIS-LL), motor nerve conduction velocity (MNCV), neuropathy symptoms and change (NSC), total severity score (TSS), neurological disability score (NDS), and vibration perception thresholds (VPT). The secondary outcome was safety parameters. Results: Eight randomized controlled trials met the inclusion criteria were selected and the efficacy and safety of Alpha lipoic acid in treating diabetic neuropathy were critically analyzed in comparison to the placebo group. The results of this systematic review and meta-analysis showed: Alpha lipoic acid has reduced HbA1c levels (Inverse variance (IV): -1.01 (-1.14 to -0.88) at 95% CI, p < 0.00001, I2 = 96%). ALA administration significantly decreased the Neuropathy Impairment Score (Inverse variance (IV): -1.18 (-1.35 to -1.02) at 95% CI, p<0.00001, I2=16%), ALA administration significantly decreased NIS-LL (Inverse variance (IV): -0.83 (-0.94 to -0.71) at 95% CI, p < 0.00001, I2 = 0%), ALA didn’t show significant improvement in MNCV Score (Inverse variance (IV): 0.07 (-0.67 to 0.81) at 95% CI, P = 0.85, I2 = 0%), ALA found to be beneficial in improving both NSC Number and NSC Severity score (Inverse variance (IV): -0.18 (-0.36 to -0.01) at 95% CI, P = 0.04, I2 = 0%) and (Inverse variance (IV): -0.64 (-0.82 to -0.47) at 95%CI, P < 0.00001, I2 = 89% ) respectively, ALA found to improve TSS (Inverse variance (IV): -0.45 (-0.61 to -0.28) at 95% CI, P < 0.00001, I2 = 98%), ALA shows significant improvement in NDS (Inverse variance (IV): -0.72 (-1.03 to -0.40) at 95% CI, p < 0.00001, I2 = 98%), ALA shows significant improvement in VPT (Inverse variance (IV): -0.36 (-0.52 to -0.20) at 95% CI, P < 0.0001, I2 = 96%) when compared with Placebo/control group. Conclusion: The findings indicate that oral treatment with 600–1800 mg of alpha-lipoic acid may improve a few symptoms resulting from diabetic neuropathy and is a safe option when given at a low dose. At higher doses, it has shown adverse effects.

show abstract

Prevalence of peripheral neuropathy among type 2 diabetes mellitus patients in a rural health centre in South India

Cited by 13 publications

References 29 publications

Diabetic peripheral neuropathy in diabetic patients attending an urban health and training centre

Diabetic peripheral neuropathy in diabetic patients attending an urban health and training centre

Prevalence and correlates of vibration perception threshold based diabetic peripheral neuropathy in Gujarati urban population: A cross sectional study

Safety and efficacy of oral Alpha lipoic acid in the management of Diabetic Neuropathy: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About